In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
15 authors.
Neetu SinghDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0009-0008-1824-1554 Esther NeedDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0009-0002-0060-5504 Ayden BerndtDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Matthew GoffDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
Lydia J WilsonDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-9959-9310 Firas MourtadaDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-4388-5334 Feng GuoDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.ORCID 0000-0003-0882-5296 Tara MastrenDepartment of Civil and Environmental Engineering, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-1289-6505 Taslim Al-HilalDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0002-9189-776X Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5458-2243 Amit MaityDepartment of Radiology Oncology, University of Utah, Salt Lake City, UT 84112, USA.
Scott C MillerDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0002-2127-1243 Satoshi MinoshimaDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84112, USA.
Shreya GoelDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0001-8927-8380 Sixiang ShiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0002-8354-7620 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 (
Indexed as
ActiniumAlpha ParticlesFolate Receptor 1Ovarian NeoplasmsAnimalsCell Line, TumorFemaleHumansMicePositron-Emission TomographyXenograft Model Antitumor AssaysActiniumActinium-225Folate Receptor 1
Identifiers
PMID42341116
PMCPMC13292942
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390